Stockreport

Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ -- 93% overall response (13 of 14 patients) and 71% complete response rates (10 of 14 patients) in follicular lymphoma grades [Read more]